Currently, there are limited therapies for endometrial cancer patients who progress on or after platinum-based chemotherapy, and prognoses for these patients are poor.ii

Dostarlimab is an investigational anti-programmed death (PD)-1 immunotherapy agent that is currently being evaluated for the treatment of recurrent or advanced endometrial cancer.

Mechanism of Action
Dostarlimab binds with high affinity to the PD-1 receptor, working to block its interaction with programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).\(^i\)

About Endometrial Cancer
Endometrial cancer is found in the inner lining of the uterus, known as the endometrium.ii It is the most common type of cancer that affects the female reproductive organs and is the sixth most prevalent cancer in women worldwide.iii Endometrial cancer has the highest rate of mismatch repair deficiency (dMMR) and microsatellite instability (MSI-H) of all tumours. Tumours with dMMR/MSI-H have increased mutation rates, making these tumours more likely to respond to anti-PD-1 or anti-PD-L1 therapy.iv,v

Dostarlimab in Clinical Trials
Dostarlimab is also being investigated in a first-line setting for advanced endometrial cancer in combination with standard of care chemotherapy.vi

Additionally, dostarlimab is being evaluated in combination with other therapeutic agents for patients with advanced solid tumours or metastatic cancer, including combinations with niraparib, a poly ADP ribose polymerase (PARP) inhibitor, and other immuno-oncology agents.

Dostarlimab in Clinical Trials in Gynaecological Cancers^vii

<table>
<thead>
<tr>
<th>Trial Name/ID</th>
<th>Status*</th>
<th>Study Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>GARNET(^i) (NCT02715284)</td>
<td>Recruiting</td>
<td>Dostarlimab in advanced solid tumours</td>
</tr>
<tr>
<td>RUBY(^i) (NCT03981795)</td>
<td>Recruiting</td>
<td>Dostarlimab plus carboplatin-paclitaxel versus placebo plus carboplatin-paclitaxel in recurrent or primary advanced endometrial cancer</td>
</tr>
<tr>
<td>MOONSTONE(^i) (NCT03935471)</td>
<td>Recruiting</td>
<td>Dostarlimab and niraparib in platinum resistant ovarian cancer</td>
</tr>
<tr>
<td>FIRST(^i) (NCT03623859)</td>
<td>Recruiting</td>
<td>Dostarlimab and niraparib versus standard of care platinum-based therapy in non-mucinous epithelial ovarian cancer (in the front-line setting)</td>
</tr>
<tr>
<td>OPAL(^i) (NCT03747398)</td>
<td>Active, not recruiting</td>
<td>Dostarlimab and niraparib in ovarian cancer</td>
</tr>
</tbody>
</table>

\(^*\) = Monotherapy
\(^i\) = In combination with other GSK therapies
\(^ii\) = As of February 2020

**References**